A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.
Sadeghi S, Plets M, Lara P, Tangen C, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian M. Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design. Journal Of Clinical Oncology 2024, 42: tps4617-tps4617. DOI: 10.1200/jco.2024.42.16_suppl.tps4617.Peer-Reviewed Original ResearchProgression free survivalMetastatic urothelial carcinomaMedian progression free survivalStandard of careOverall survivalEnfortumab vedotinSacituzumab govitecanFree survivalCisplatin-ineligible metastatic urothelial carcinomaPhase III randomized trialMedian overall survivalStudies of eribulinEndpoint of OSFGFR alterationsLiver metastasesSystemic therapyEligible ptsUrothelial carcinomaPrimary endpointGenitourinary cancersTreatment changesEribulinResponse rateActivity of EORRSWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]
Kim H, Tangen C, Vaishampayan U, Tripathi A, Patel S, Shuch B, Barata P, Tan A, Esfeller L, Lara P, Sanchez A, Lerner S, Thompson I. SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars And Original Investigations 2024, 42: s4. DOI: 10.1016/j.urolonc.2024.01.044.Peer-Reviewed Original ResearchCytoreductive nephrectomyPrimary tumorImmune checkpointsSystemic therapySurvival outcomesTrials of immune checkpoint inhibitorsHigher neoantigen loadPROBE study designImmune checkpoint inhibitorsSynchronous primary tumorsAdvanced renal cancerWeeks of therapyOverall survival outcomesShorter survival outcomeStandard of careCARMENA trialNeoantigen loadSunitinib therapyAdvanced RCCAntigen spreadingImmune therapyUrologic evaluationFrontline settingCombination therapySurgical candidatesSWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
Maughan B, Plets M, Pal S, Ged Y, Tangen C, Vaishampayan U, Lerner S, Thompson I. SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC). Journal Of Clinical Oncology 2024, 42: tps493-tps493. DOI: 10.1200/jco.2024.42.4_suppl.tps493.Peer-Reviewed Original ResearchPapillary renal cell carcinomaProgression free survivalMedian progression free survivalImmune therapyAdvanced papillary renal cell carcinomaComparison of progression free survivalClinical trialsPhase II randomized trialObjective response rateLines of therapyPresence of metastasesRenal cell carcinomaSignificant autoimmune diseaseSingle arm trialRandomized clinical trialsStandard of careAdjuvant pembrolizumabFree survivalMetastatic diseaseOverall survivalCell carcinomaPrimary endpointPathological confirmationSecondary endpointsTargeted therapy